34
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ethnopharmacological Approaches for Therapy of Jaundice: Part II. Highly Used Plant Species from Acanthaceae, Euphorbiaceae, Asteraceae, Combretaceae, and Fabaceae Families

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In many developing countries, jaundice is the common symptom of hepatic diseases which are a major cause of mortality. The use of natural product-based therapies is very popular for such hepatic disorders. A great number of medicinal plants have been utilized for this purpose and some facilitated the discovery of active compounds which helped the development of new synthetic drugs against jaundice. However, more epidemiological studies and clinical trials are required for the practical implementation of the plant pharmacotherapy of jaundice. The focus of this second part of our review is on several of the most prominent plants used against jaundice identified in the analysis performed in the first part of the review viz. Andrographis paniculata (Burm.f.) Nees, Silybum marianum (L.) Gaertn., Terminalia chebula Retz., Glycyrrhiza glabra L. and some species of genus Phyllanthus. Furthermore, we discuss their physiological effects, biologically active ingredients, and the potential mechanisms of action. Some of the most important active ingredients were silybin (also recommended by German commission), phyllanthin and andrographolide, whose action leads to bilirubin reduction and normalization of the levels of relevant serum enzymes indicative for the pathophysiological status of the liver.

          Related collections

          Most cited references192

          • Record: found
          • Abstract: found
          • Article: not found

          Review of Pharmacological Effects of Glycyrrhiza sp. and its Bioactive Compounds

          Abstract The roots and rhizomes of licorice (Glycyrrhiza) species have long been used worldwide as a herbal medicine and natural sweetener. Licorice root is a traditional medicine used mainly for the treatment of peptic ulcer, hepatitis C, and pulmonary and skin diseases, although clinical and experimental studies suggest that it has several other useful pharmacological properties such as antiinflammatory, antiviral, antimicrobial, antioxidative, anticancer activities, immunomodulatory, hepatoprotective and cardioprotective effects. A large number of components have been isolated from licorice, including triterpene saponins, flavonoids, isoflavonoids and chalcones, with glycyrrhizic acid normally being considered to be the main biologically active component. This review summarizes the phytochemical, pharmacological and pharmacokinetics data, together with the clinical and adverse effects of licorice and its bioactive components. Copyright © 2008 John Wiley & Sons, Ltd.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Milk thistle (Silybum marianum) for the therapy of liver disease.

            Silymarin, derived from the milk thistle plant, Silybum marianum, has been used for centuries as a natural remedy for diseases of the liver and biliary tract. As interest in alternative therapy has emerged in the United States, gastroenterologists have encountered increasing numbers of patients taking silymarin with little understanding of its purported properties. Silymarin and its active constituent, silybin, have been reported to work as antioxidants scavenging free radicals and inhibiting lipid peroxidation. Studies also suggest that they protect against genomic injury, increase hepatocyte protein synthesis, decrease the activity of tumor promoters, stabilize mast cells, chelate iron, and slow calcium metabolism. In this article we review silymarin's history, pharmacology, and properties, and the clinical trials pertaining to patients with acute and chronic liver disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A phase I trial of andrographolide in HIV positive patients and normal volunteers.

              A phase I dose-escalating clinical trial of andrographolide from Andrographis paniculata was conducted in 13 HIV positive patients and five HIV uninfected, healthy volunteers. The objectives were primarily to assess safety and tolerability and secondarily to assess effects on plasma virion HIV-1 RNA levels and CD4(+) lymphocyte levels. No subjects used antiretroviral medications during the trial. Those with liver or renal abnormalities were excluded. The planned regimen was 5 mg/kg bodyweight for 3 weeks, escalating to 10 mg/kg bodyweight for 3 weeks, and to 20 mg/kg bodyweight for a final 3 weeks. The trial was interrupted at 6 weeks due to adverse events including an anaphylactic reaction in one patient. All adverse events had resolved by the end of observation. A significant rise in the mean CD4(+) lymphocyte level of HIV subjects occurred after administration of 10 mg/kg andrographolide (from a baseline of 405 cells/mm(3) to 501 cells/mm(3); p = 0.002). There were no statistically significant changes in mean plasma HIV-1 RNA levels throughout the trial. Andrographolide may inhibit HIV-induced cell cycle dysregulation, leading to a rise in CD4(+) lymphocyte levels in HIV-1 infected individuals. Copyright 2000 John Wiley & Sons, Ltd.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                10 August 2017
                2017
                : 8
                : 519
                Affiliations
                [1] 1Department of Pharmaceutical Sciences, Faculty of Technology, Kumaun University Nainital, India
                [2] 2Department of Pharmaceutical Botany, “Iuliu Haţieganu” University of Medicine and Pharmacy Cluj-Napoca, Romania
                [3] 3ICHAT and Institute for Life Sciences, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, Romania
                [4] 4Division BIOCEV, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic Prague, Czechia
                [5] 5Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences Tehran, Iran
                [6] 6Institute of Genetics and Animal Breeding of the Polish Academy of Sciences Jastrzebiec, Poland
                [7] 7School of Medical Sciences, Universiti Sains Malaysia Kota Bharu, Malaysia
                [8] 8Department of Public Health, Xi’an Jiaotong-Liverpool University Suzhou, China
                [9] 9Department of Pharmacognosy, University of Vienna Vienna, Austria
                [10] 10Department of Vascular Biology and Thrombosis Research, Centre for Physiology and Pharmacology, Medical University of Vienna Vienna, Austria
                Author notes

                Edited by: Jianbo Xiao, University of Macau, China

                Reviewed by: Gokhan Zengin, Selçuk University, Turkey; Rene Cardenas, National Autonomous University of Mexico, Mexico

                *Correspondence: Atanas G. Atanasov, a.atanasov.mailbox@ 123456gmail.com

                These authors have contributed equally to this work.

                This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

                Article
                10.3389/fphar.2017.00519
                5554347
                28848436
                fcd291f0-4e29-42fc-91b5-790f394618c8
                Copyright © 2017 Tewari, Mocan, Parvanov, Sah, Nabavi, Huminiecki, Ma, Lee, Horbańczuk and Atanasov.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 17 February 2017
                : 24 July 2017
                Page count
                Figures: 6, Tables: 0, Equations: 0, References: 208, Pages: 14, Words: 0
                Categories
                Pharmacology
                Review

                Pharmacology & Pharmaceutical medicine
                jaundice,bilirubin,oxidative stress,traditional use,phytoconstituents,serum enzymes,alkaline phosphatase

                Comments

                Comment on this article